DEC 02, 2021 3:00 AM PST

A New Method to Enhance Immunotherapy in Mouse Tumors

WRITTEN BY: Katie Kokolus

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, accounting for about 90% of pancreatic cancer diagnoses.  PDAC tumors are highly immunosuppressive, which means they evade mechanisms of the immune system.  Therefore, these tumors are very aggressive, and treatment options are limited.

Immune checkpoint inhibitors (ICI) are immunotherapy drugs that block the binding of immune checkpoints with their partner proteins. Under normal conditions, immune checkpoints regulate the immune response to prevent autoimmune responses.  However, the blockade provided by ICIs prevents the checkpoints from turning down the activity of cancer-killing immune cells.  Thus, the use of ICIs promotes and extends the anti-cancer activities of immune cells.

Unfortunately, the immunosuppressive nature of PDAC, along with the low number of immune cells which typically enter the tumor, ICIs fail to control tumor growth.  Tumors that exhibit these characteristics are sometimes called “cold” tumors because they do not initiate a robust immune response.  Alternatively, “hot” tumors exhibit strong immune activity and are usually filled with many anti-cancer immune cells.  Because hot tumors respond to ICIs much more efficiently than cold tumors, there is a critical need to develop therapeutic methods which turn cold tumors hot

A study published in the Journal for Immunotherapy of Cancer demonstrates a novel method of sensitizing mouse tumors to the popular ICI anti-PD-1. The study utilizes a drug that inhibits a protein called dipeptidyl peptidase (DPP).

The research team administered an oral DPP inhibitor to mice with PDAC tumors.  Using a variety of immunological techniques, the researchers examined how DDP inhibition altered the immune status of the tumors.  The study demonstrated that anti-tumor immune cells, including natural kills (NK) cells and T cells.  The increased immune cell infiltration was accompanied by slowed tumor growth and improved efficacy of anti-PD-1 therapy. 

Importantly, mice treated with combination therapy consisting of DPP and PD-1 inhibition developed immune memory demonstrated by rejection of tumors following re-exposure.  This finding suggests that this combination therapy could potentially protect from cancer recurrence.

The authors summarize that their study underscores the importance of DPPs in PDAC development.   They also conclude that DPP inhibition enhances natural anti-tumor immunity and ICI effectiveness in mouse models of PDAC.  The data presents a strong rationale for exploring clinical development of a combination DPP/PD-1 inhibition strategy. 

Sources: PDAC, ICI, cold, hot, turn cold tumors hot, Journal for ImmunoTherapy of Cancer, PD-1, DPP, NK, T cells

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
AUG 29, 2021
Cancer
Researchers Bioprint Deadly Brain Tumor with 3D Printer
AUG 29, 2021
Researchers Bioprint Deadly Brain Tumor with 3D Printer
Researchers have managed to print an entire active and viable glioblastoma tumor- the deadliest form of brain cancer- us ...
OCT 04, 2021
Cancer
Predicting Progression-Free Survival in a Melanoma Study
OCT 04, 2021
Predicting Progression-Free Survival in a Melanoma Study
IsoPlexis’ Single-Cell Proteomics Predict Progression-Free Survival in Melanoma Study While advancements in oncolo ...
OCT 01, 2021
Health & Medicine
Eppendorf Award 2022: Call for Entries
OCT 01, 2021
Eppendorf Award 2022: Call for Entries
Eppendorf Award 2022: Call for Entries The Eppendorf Award for Young European Investigators, endowed with 20,000 EUR, is ...
OCT 25, 2021
Cell & Molecular Biology
The Labroots 2021 Cell Biology Virtual Event Poster Winner: 5-Azacytidine Treatment & Lung Cancer
OCT 25, 2021
The Labroots 2021 Cell Biology Virtual Event Poster Winner: 5-Azacytidine Treatment & Lung Cancer
Labroots virtual events are a great place to share research and learn about others work. These events feature participan ...
NOV 11, 2021
Clinical & Molecular DX
Cancer Pathologist Burnout? AI to the Rescue.
NOV 11, 2021
Cancer Pathologist Burnout? AI to the Rescue.
Diagnosing cancer is hard work. The challenging demands of their caseloads see diagnostic pathologists in many clinical ...
Loading Comments...